Strategic Acquisition PrecisionMed has a recent acquisition history, including BioIVT acquiring the company in 2023, which suggests integration into a larger biospecimen and service ecosystem. Leverage cross-sell opportunities with BioIVT’s network and existing pharma/biotech clients to offer expanded sample types and data services.

Rich Sample Portfolio As a leading supplier of longitudinally collected human cerebrospinal fluid and blood samples with detailed clinical data, PrecisionMed holds high-value, well-annotated biospecimens. Target pharmaceutical and biotech companies conducting CNS, biomarker, and precision medicine research for partnerships, contract research, and bespoke sample access.

US IRB Provenance Samples are collected under U.S. IRB-approved protocols with broad therapeutic and diagnostic coverage. This regulatory rigor can be positioned to reduce risk for researchers and help accelerate study timelines when engaging with contract services, diagnostics developers, and clinical trial suppliers.

Blue-Chip Customer Base A diversified clientele including nearly every major pharma/biotech and top academic/government labs signals strong demand and credibility. Pursue enterprise partnerships, volume-based pricing, and data-enabled service bundles to lock in long-term research programs.

Growth Through Data & Tech Existing tech stack with cloud platforms and modern web tools indicates capacity for scalable data services, analytics, and sample logistics. Propose value adds such as integrated data platforms, biomarker discovery support, and collaborative research dashboards to attract data-intensive projects.